Injectable dual thermoreversible hydrogel for sustained intramuscular drug delivery

Herein, we reported novel docetaxel-decorated solid lipid nanoparticle (DCT-SLN)-loaded dual thermoreversible system (DCT-DRTS) for intramuscular administration with reduced burst effect, sustained release and improved antitumor efficacy. The optimized DCT-DRTs was subjected to in-vitro and in-vivo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of controlled release 2024-10, Vol.374, p.590-605
Hauptverfasser: Din, Fakhar Ud, Kim, Jung Suk, Lee, Ho Cheol, Cheon, Seunghyun, Woo, Mi Ran, Woo, Sanghyun, Ku, Sae Kwang, Yoo, Hye Hyun, Kim, Jong Oh, Jin, Sung Giu, Choi, Han-Gon
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 605
container_issue
container_start_page 590
container_title Journal of controlled release
container_volume 374
creator Din, Fakhar Ud
Kim, Jung Suk
Lee, Ho Cheol
Cheon, Seunghyun
Woo, Mi Ran
Woo, Sanghyun
Ku, Sae Kwang
Yoo, Hye Hyun
Kim, Jong Oh
Jin, Sung Giu
Choi, Han-Gon
description Herein, we reported novel docetaxel-decorated solid lipid nanoparticle (DCT-SLN)-loaded dual thermoreversible system (DCT-DRTS) for intramuscular administration with reduced burst effect, sustained release and improved antitumor efficacy. The optimized DCT-DRTs was subjected to in-vitro and in-vivo analyses. Antitumor evaluation of the DCT-DRTS was executed and compared with DCT-hydrogel, and DCT-suspension trailed by the histopathological and immune-histochemical analyses. The DCT-SLN gave a mean particle size of 157 nm and entrapment efficiency of 93 %. It was a solid at room temperature, and changed to liquid at physiological temperature due to its melting point of about 32 °C. Unlikely, poloxamer mixture remained liquefied at 25-27 °C, however converted to gel at physiological temperature. This behavior demonstrated opposed reversible property of the DCT-SLN and poloxamer hydrogel in DCT-DRTS system, making it ideal for intramuscular administration and quick gelation inside the body. The DCT-DRTS sustained the drugs release and unlike DCT-hydrogel, the preliminary plasma concentration of DCT-DRTS was significantly reduced, overcoming the burst release. A meaningfully enhanced antitumor efficacy and improved survival rate was observed from DCT-DRTS in tumor cell xenograft athymic nude mice. Additionally, increased apoptotic and reduced proliferation markers were observed in DCT-DRTS treated tumor masses. It was concluded that DCT-DRTS may be a suitable choice for intramuscular administration of DCT with sustained release, improved bioavailability, reduced toxicity and enhanced antitumor effects. [Display omitted] •Docetaxel (DCT), has been used extensively for the treatment of various cancers.•We developed a novel sustained release formulation DCT-DRTS for intramuscular route.•DCT-DRTS was composed of thermosensitive solid lipid nanoparticle and hydrogel.•It demonstrated improved bioavailability, no toxicity and greater antitumor effects.•High apoptosis and reduced proliferation of tumor masses were observed in DCT-DRTS.
doi_str_mv 10.1016/j.jconrel.2024.08.034
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3099799643</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365924005844</els_id><sourcerecordid>3099799643</sourcerecordid><originalsourceid>FETCH-LOGICAL-c243t-2335749f2ab81c2bce413568a8b442e82093b1d2ca3b2f4a6aee84d5c13bdc3a3</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhoMoun78BKVHL61JJu0mJxHxCxY8qOeQJlNNSVtNWmH_vV129eppYHjeeZmHkHNGC0ZZddUWrR36iKHglIuCyoKC2CMLJpeQC6XKfbKYOZlDVaojcpxSSyktQSwPyREoTqWCakFenvoW7WjqgJmbTMjGD4zdEPEbY_Kb7cfaxeEdQ9YMMUtTGo3v0WW-H6PppmSnYGLm4vSeOQx-jq1PyUFjQsKz3Twhb_d3r7eP-er54en2ZpVbLmDMOUC5FKrhppbM8tqiYFBW0shaCI6SUwU1c9waqHkjTGUQpXClZVA7CwZOyOX27mccviZMo-58shiC6XGYkgaq1FKpSsCMllvUxiGliI3-jL4zca0Z1RufutU7n3rjU1OpZ59z7mJXMdUdur_Ur8AZuN4COD_67THqZD32Fp2Ps1ftBv9PxQ8miYtz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3099799643</pqid></control><display><type>article</type><title>Injectable dual thermoreversible hydrogel for sustained intramuscular drug delivery</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Din, Fakhar Ud ; Kim, Jung Suk ; Lee, Ho Cheol ; Cheon, Seunghyun ; Woo, Mi Ran ; Woo, Sanghyun ; Ku, Sae Kwang ; Yoo, Hye Hyun ; Kim, Jong Oh ; Jin, Sung Giu ; Choi, Han-Gon</creator><creatorcontrib>Din, Fakhar Ud ; Kim, Jung Suk ; Lee, Ho Cheol ; Cheon, Seunghyun ; Woo, Mi Ran ; Woo, Sanghyun ; Ku, Sae Kwang ; Yoo, Hye Hyun ; Kim, Jong Oh ; Jin, Sung Giu ; Choi, Han-Gon</creatorcontrib><description>Herein, we reported novel docetaxel-decorated solid lipid nanoparticle (DCT-SLN)-loaded dual thermoreversible system (DCT-DRTS) for intramuscular administration with reduced burst effect, sustained release and improved antitumor efficacy. The optimized DCT-DRTs was subjected to in-vitro and in-vivo analyses. Antitumor evaluation of the DCT-DRTS was executed and compared with DCT-hydrogel, and DCT-suspension trailed by the histopathological and immune-histochemical analyses. The DCT-SLN gave a mean particle size of 157 nm and entrapment efficiency of 93 %. It was a solid at room temperature, and changed to liquid at physiological temperature due to its melting point of about 32 °C. Unlikely, poloxamer mixture remained liquefied at 25-27 °C, however converted to gel at physiological temperature. This behavior demonstrated opposed reversible property of the DCT-SLN and poloxamer hydrogel in DCT-DRTS system, making it ideal for intramuscular administration and quick gelation inside the body. The DCT-DRTS sustained the drugs release and unlike DCT-hydrogel, the preliminary plasma concentration of DCT-DRTS was significantly reduced, overcoming the burst release. A meaningfully enhanced antitumor efficacy and improved survival rate was observed from DCT-DRTS in tumor cell xenograft athymic nude mice. Additionally, increased apoptotic and reduced proliferation markers were observed in DCT-DRTS treated tumor masses. It was concluded that DCT-DRTS may be a suitable choice for intramuscular administration of DCT with sustained release, improved bioavailability, reduced toxicity and enhanced antitumor effects. [Display omitted] •Docetaxel (DCT), has been used extensively for the treatment of various cancers.•We developed a novel sustained release formulation DCT-DRTS for intramuscular route.•DCT-DRTS was composed of thermosensitive solid lipid nanoparticle and hydrogel.•It demonstrated improved bioavailability, no toxicity and greater antitumor effects.•High apoptosis and reduced proliferation of tumor masses were observed in DCT-DRTS.</description><identifier>ISSN: 0168-3659</identifier><identifier>ISSN: 1873-4995</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2024.08.034</identifier><identifier>PMID: 39208936</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject><![CDATA[Animals ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - pharmacokinetics ; Bioavailability ; Burst effect ; Cell Line, Tumor ; Delayed-Action Preparations - chemistry ; Docetaxel ; Docetaxel - administration & dosage ; Docetaxel - pharmacokinetics ; Drug Carriers - chemistry ; Drug Delivery Systems ; Drug Liberation ; Dual thermoreversible system ; Female ; Humans ; Hydrogels - administration & dosage ; Hydrogels - chemistry ; Injections, Intramuscular ; Lipids - administration & dosage ; Lipids - chemistry ; Liposomes ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Nanoparticles - administration & dosage ; Nanoparticles - chemistry ; Neoplasms - drug therapy ; Poloxamer - chemistry ; Solid lipid nanoparticles ; Sustained release ; Taxoids - administration & dosage ; Taxoids - chemistry ; Taxoids - pharmacokinetics ; Temperature ; Tumor]]></subject><ispartof>Journal of controlled release, 2024-10, Vol.374, p.590-605</ispartof><rights>2024 Elsevier B.V.</rights><rights>Copyright © 2024 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c243t-2335749f2ab81c2bce413568a8b442e82093b1d2ca3b2f4a6aee84d5c13bdc3a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jconrel.2024.08.034$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39208936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Din, Fakhar Ud</creatorcontrib><creatorcontrib>Kim, Jung Suk</creatorcontrib><creatorcontrib>Lee, Ho Cheol</creatorcontrib><creatorcontrib>Cheon, Seunghyun</creatorcontrib><creatorcontrib>Woo, Mi Ran</creatorcontrib><creatorcontrib>Woo, Sanghyun</creatorcontrib><creatorcontrib>Ku, Sae Kwang</creatorcontrib><creatorcontrib>Yoo, Hye Hyun</creatorcontrib><creatorcontrib>Kim, Jong Oh</creatorcontrib><creatorcontrib>Jin, Sung Giu</creatorcontrib><creatorcontrib>Choi, Han-Gon</creatorcontrib><title>Injectable dual thermoreversible hydrogel for sustained intramuscular drug delivery</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>Herein, we reported novel docetaxel-decorated solid lipid nanoparticle (DCT-SLN)-loaded dual thermoreversible system (DCT-DRTS) for intramuscular administration with reduced burst effect, sustained release and improved antitumor efficacy. The optimized DCT-DRTs was subjected to in-vitro and in-vivo analyses. Antitumor evaluation of the DCT-DRTS was executed and compared with DCT-hydrogel, and DCT-suspension trailed by the histopathological and immune-histochemical analyses. The DCT-SLN gave a mean particle size of 157 nm and entrapment efficiency of 93 %. It was a solid at room temperature, and changed to liquid at physiological temperature due to its melting point of about 32 °C. Unlikely, poloxamer mixture remained liquefied at 25-27 °C, however converted to gel at physiological temperature. This behavior demonstrated opposed reversible property of the DCT-SLN and poloxamer hydrogel in DCT-DRTS system, making it ideal for intramuscular administration and quick gelation inside the body. The DCT-DRTS sustained the drugs release and unlike DCT-hydrogel, the preliminary plasma concentration of DCT-DRTS was significantly reduced, overcoming the burst release. A meaningfully enhanced antitumor efficacy and improved survival rate was observed from DCT-DRTS in tumor cell xenograft athymic nude mice. Additionally, increased apoptotic and reduced proliferation markers were observed in DCT-DRTS treated tumor masses. It was concluded that DCT-DRTS may be a suitable choice for intramuscular administration of DCT with sustained release, improved bioavailability, reduced toxicity and enhanced antitumor effects. [Display omitted] •Docetaxel (DCT), has been used extensively for the treatment of various cancers.•We developed a novel sustained release formulation DCT-DRTS for intramuscular route.•DCT-DRTS was composed of thermosensitive solid lipid nanoparticle and hydrogel.•It demonstrated improved bioavailability, no toxicity and greater antitumor effects.•High apoptosis and reduced proliferation of tumor masses were observed in DCT-DRTS.</description><subject>Animals</subject><subject>Antineoplastic Agents - administration &amp; dosage</subject><subject>Antineoplastic Agents - pharmacokinetics</subject><subject>Bioavailability</subject><subject>Burst effect</subject><subject>Cell Line, Tumor</subject><subject>Delayed-Action Preparations - chemistry</subject><subject>Docetaxel</subject><subject>Docetaxel - administration &amp; dosage</subject><subject>Docetaxel - pharmacokinetics</subject><subject>Drug Carriers - chemistry</subject><subject>Drug Delivery Systems</subject><subject>Drug Liberation</subject><subject>Dual thermoreversible system</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrogels - administration &amp; dosage</subject><subject>Hydrogels - chemistry</subject><subject>Injections, Intramuscular</subject><subject>Lipids - administration &amp; dosage</subject><subject>Lipids - chemistry</subject><subject>Liposomes</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Nude</subject><subject>Nanoparticles - administration &amp; dosage</subject><subject>Nanoparticles - chemistry</subject><subject>Neoplasms - drug therapy</subject><subject>Poloxamer - chemistry</subject><subject>Solid lipid nanoparticles</subject><subject>Sustained release</subject><subject>Taxoids - administration &amp; dosage</subject><subject>Taxoids - chemistry</subject><subject>Taxoids - pharmacokinetics</subject><subject>Temperature</subject><subject>Tumor</subject><issn>0168-3659</issn><issn>1873-4995</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LxDAQhoMoun78BKVHL61JJu0mJxHxCxY8qOeQJlNNSVtNWmH_vV129eppYHjeeZmHkHNGC0ZZddUWrR36iKHglIuCyoKC2CMLJpeQC6XKfbKYOZlDVaojcpxSSyktQSwPyREoTqWCakFenvoW7WjqgJmbTMjGD4zdEPEbY_Kb7cfaxeEdQ9YMMUtTGo3v0WW-H6PppmSnYGLm4vSeOQx-jq1PyUFjQsKz3Twhb_d3r7eP-er54en2ZpVbLmDMOUC5FKrhppbM8tqiYFBW0shaCI6SUwU1c9waqHkjTGUQpXClZVA7CwZOyOX27mccviZMo-58shiC6XGYkgaq1FKpSsCMllvUxiGliI3-jL4zca0Z1RufutU7n3rjU1OpZ59z7mJXMdUdur_Ur8AZuN4COD_67THqZD32Fp2Ps1ftBv9PxQ8miYtz</recordid><startdate>202410</startdate><enddate>202410</enddate><creator>Din, Fakhar Ud</creator><creator>Kim, Jung Suk</creator><creator>Lee, Ho Cheol</creator><creator>Cheon, Seunghyun</creator><creator>Woo, Mi Ran</creator><creator>Woo, Sanghyun</creator><creator>Ku, Sae Kwang</creator><creator>Yoo, Hye Hyun</creator><creator>Kim, Jong Oh</creator><creator>Jin, Sung Giu</creator><creator>Choi, Han-Gon</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202410</creationdate><title>Injectable dual thermoreversible hydrogel for sustained intramuscular drug delivery</title><author>Din, Fakhar Ud ; Kim, Jung Suk ; Lee, Ho Cheol ; Cheon, Seunghyun ; Woo, Mi Ran ; Woo, Sanghyun ; Ku, Sae Kwang ; Yoo, Hye Hyun ; Kim, Jong Oh ; Jin, Sung Giu ; Choi, Han-Gon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c243t-2335749f2ab81c2bce413568a8b442e82093b1d2ca3b2f4a6aee84d5c13bdc3a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - administration &amp; dosage</topic><topic>Antineoplastic Agents - pharmacokinetics</topic><topic>Bioavailability</topic><topic>Burst effect</topic><topic>Cell Line, Tumor</topic><topic>Delayed-Action Preparations - chemistry</topic><topic>Docetaxel</topic><topic>Docetaxel - administration &amp; dosage</topic><topic>Docetaxel - pharmacokinetics</topic><topic>Drug Carriers - chemistry</topic><topic>Drug Delivery Systems</topic><topic>Drug Liberation</topic><topic>Dual thermoreversible system</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrogels - administration &amp; dosage</topic><topic>Hydrogels - chemistry</topic><topic>Injections, Intramuscular</topic><topic>Lipids - administration &amp; dosage</topic><topic>Lipids - chemistry</topic><topic>Liposomes</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Nude</topic><topic>Nanoparticles - administration &amp; dosage</topic><topic>Nanoparticles - chemistry</topic><topic>Neoplasms - drug therapy</topic><topic>Poloxamer - chemistry</topic><topic>Solid lipid nanoparticles</topic><topic>Sustained release</topic><topic>Taxoids - administration &amp; dosage</topic><topic>Taxoids - chemistry</topic><topic>Taxoids - pharmacokinetics</topic><topic>Temperature</topic><topic>Tumor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Din, Fakhar Ud</creatorcontrib><creatorcontrib>Kim, Jung Suk</creatorcontrib><creatorcontrib>Lee, Ho Cheol</creatorcontrib><creatorcontrib>Cheon, Seunghyun</creatorcontrib><creatorcontrib>Woo, Mi Ran</creatorcontrib><creatorcontrib>Woo, Sanghyun</creatorcontrib><creatorcontrib>Ku, Sae Kwang</creatorcontrib><creatorcontrib>Yoo, Hye Hyun</creatorcontrib><creatorcontrib>Kim, Jong Oh</creatorcontrib><creatorcontrib>Jin, Sung Giu</creatorcontrib><creatorcontrib>Choi, Han-Gon</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Din, Fakhar Ud</au><au>Kim, Jung Suk</au><au>Lee, Ho Cheol</au><au>Cheon, Seunghyun</au><au>Woo, Mi Ran</au><au>Woo, Sanghyun</au><au>Ku, Sae Kwang</au><au>Yoo, Hye Hyun</au><au>Kim, Jong Oh</au><au>Jin, Sung Giu</au><au>Choi, Han-Gon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Injectable dual thermoreversible hydrogel for sustained intramuscular drug delivery</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2024-10</date><risdate>2024</risdate><volume>374</volume><spage>590</spage><epage>605</epage><pages>590-605</pages><issn>0168-3659</issn><issn>1873-4995</issn><eissn>1873-4995</eissn><abstract>Herein, we reported novel docetaxel-decorated solid lipid nanoparticle (DCT-SLN)-loaded dual thermoreversible system (DCT-DRTS) for intramuscular administration with reduced burst effect, sustained release and improved antitumor efficacy. The optimized DCT-DRTs was subjected to in-vitro and in-vivo analyses. Antitumor evaluation of the DCT-DRTS was executed and compared with DCT-hydrogel, and DCT-suspension trailed by the histopathological and immune-histochemical analyses. The DCT-SLN gave a mean particle size of 157 nm and entrapment efficiency of 93 %. It was a solid at room temperature, and changed to liquid at physiological temperature due to its melting point of about 32 °C. Unlikely, poloxamer mixture remained liquefied at 25-27 °C, however converted to gel at physiological temperature. This behavior demonstrated opposed reversible property of the DCT-SLN and poloxamer hydrogel in DCT-DRTS system, making it ideal for intramuscular administration and quick gelation inside the body. The DCT-DRTS sustained the drugs release and unlike DCT-hydrogel, the preliminary plasma concentration of DCT-DRTS was significantly reduced, overcoming the burst release. A meaningfully enhanced antitumor efficacy and improved survival rate was observed from DCT-DRTS in tumor cell xenograft athymic nude mice. Additionally, increased apoptotic and reduced proliferation markers were observed in DCT-DRTS treated tumor masses. It was concluded that DCT-DRTS may be a suitable choice for intramuscular administration of DCT with sustained release, improved bioavailability, reduced toxicity and enhanced antitumor effects. [Display omitted] •Docetaxel (DCT), has been used extensively for the treatment of various cancers.•We developed a novel sustained release formulation DCT-DRTS for intramuscular route.•DCT-DRTS was composed of thermosensitive solid lipid nanoparticle and hydrogel.•It demonstrated improved bioavailability, no toxicity and greater antitumor effects.•High apoptosis and reduced proliferation of tumor masses were observed in DCT-DRTS.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>39208936</pmid><doi>10.1016/j.jconrel.2024.08.034</doi><tpages>16</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0168-3659
ispartof Journal of controlled release, 2024-10, Vol.374, p.590-605
issn 0168-3659
1873-4995
1873-4995
language eng
recordid cdi_proquest_miscellaneous_3099799643
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Animals
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - pharmacokinetics
Bioavailability
Burst effect
Cell Line, Tumor
Delayed-Action Preparations - chemistry
Docetaxel
Docetaxel - administration & dosage
Docetaxel - pharmacokinetics
Drug Carriers - chemistry
Drug Delivery Systems
Drug Liberation
Dual thermoreversible system
Female
Humans
Hydrogels - administration & dosage
Hydrogels - chemistry
Injections, Intramuscular
Lipids - administration & dosage
Lipids - chemistry
Liposomes
Male
Mice
Mice, Inbred BALB C
Mice, Nude
Nanoparticles - administration & dosage
Nanoparticles - chemistry
Neoplasms - drug therapy
Poloxamer - chemistry
Solid lipid nanoparticles
Sustained release
Taxoids - administration & dosage
Taxoids - chemistry
Taxoids - pharmacokinetics
Temperature
Tumor
title Injectable dual thermoreversible hydrogel for sustained intramuscular drug delivery
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T10%3A20%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Injectable%20dual%20thermoreversible%20hydrogel%20for%20sustained%20intramuscular%20drug%20delivery&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Din,%20Fakhar%20Ud&rft.date=2024-10&rft.volume=374&rft.spage=590&rft.epage=605&rft.pages=590-605&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2024.08.034&rft_dat=%3Cproquest_cross%3E3099799643%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3099799643&rft_id=info:pmid/39208936&rft_els_id=S0168365924005844&rfr_iscdi=true